EC Number   |
Activating Compound |
Reference |
|---|
   3.4.21.68 | adenosine |
potentiates mast cell tPA activity and tPA gene expression, abolished in the presence of adenosine deaminase |
717938 |
| 3.4.21.68 | bradykinin |
endothelium-dependent vasodilator that stimulates the release of t-PA. Causes a dose-dependent increase in plasma t-PA antigen and activity concentrations in the infused arm of both pregnant and non-pregnant women. The increase in t-PA activity is greater in the nonpregnant women. Bradykinin increases the net release of t-PA antigen and activity in both pregnant women and non-pregnant women. Both net release of active t-PA and plasma t-PA/plasminogen activator inhibitor type 1 ratios are markedly reduced in pregnant women |
699868 |
| 3.4.21.68 | cyanogen bromide fibrinogen digest (FIBGN) |
FIBGN is required for the detection of tPA activity chromogenically |
683709 |
| 3.4.21.68 | cyanogen bromide-treated fibrinogen (CNBr-Fbg) |
CNBr-Fbg (50 microgram/ml) give a 10-fold enhancement of activation, and addition of 2.86 microg/ml oversulfated chondroitin-6-sulfate or oversulfated fucoidan amplified this to 15-fold. A 25-fold to 35-fold enhancement of activation of glutamic plasminogen by tPA is obtained when 2.86 microgram/ml oversulfated compounds are combined with 16.2 mmol/l lysine and 50 microgram/ml CNBr-Fbg |
683278 |
| 3.4.21.68 | dibutyryl-cAMP |
slightly increases level of tPA mRNA expression. Concentration-dependently increases tPA activity in both basal and lipopolysaccharide-stimulated rat primary astrocytes. Treatment with 100 micromol increases tPA activity by 757.9% compared with lipopolysaccharide treatment. Differentially modulates MMP-9 and tPA activity through a mechanism related to PKA activation. Co-treatment with lipopolysaccharide and dibutyryl-cAMP does not have an additive effect on tPA mRNA induction |
700431 |
| 3.4.21.68 | epinephrine |
intrabrachial infusion of epinephrine (0.1 to 0.3 microg/100 ml per minute) induces greater t-PA release in normotensive subjects as compared with essential hypertensive patients |
698204 |
| 3.4.21.68 | Fibrin |
- |
29579 |
| 3.4.21.68 | Fibrin |
activates the wild-type enzyme, and also the chimeric mutant enzyme, the latter to an extremely higher degree, overview |
731733 |
| 3.4.21.68 | Fibrin |
activity of wild-type t-PA is stimulated by |
651864 |
| 3.4.21.68 | Fibrin |
enhances activity |
29572, 29575, 29578, 29580, 29583 |
